SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]:
SEC Accession No. 0001493152-21-026729
Filing Date
2021-10-29
Accepted
2021-10-29 16:15:18
Documents
6
Period of Report
2021-07-31

Document Format Files

Seq Description Document Type Size
1 form40-f.htm 40-F 93115
2 ex99-4.htm EX-99.4 18702
3 ex99-5.htm EX-99.5 19241
4 ex99-6.htm EX-99.6 7122
5 ex99-7.htm EX-99.7 7605
6 ex99-8.htm EX-99.8 4731
  Complete submission text file 0001493152-21-026729.txt   151650
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 40-F | Act: 34 | File No.: 001-40101 | Film No.: 211363405
SIC: 2834 Pharmaceutical Preparations